NutriBand (NTRB) Capital Expenditures (2021 - 2025)
NutriBand (NTRB) posted Capital Expenditures of $5324.0 for Q2 2025, down 88.66% sequentially from $46958.0 in Q4 2024, and down 14.06% YoY from $6195.0 in Q2 2024.
NutriBand (NTRB) Capital Expenditures (2021 - 2025) Analysis & Trends
NutriBand has reported Capital Expenditures for 5 years, with the latest figure at $5324.0 in Q2 2025.
- Quarterly Capital Expenditures fell 14.06% year-over-year to $5324.0 in Q2 2025, while the trailing twelve-month figure through Jan 2026 was $5324.0 (down 94.22% YoY) and the FY2026 annual result came in at $5324.0, down 94.22% from the prior year.
- Capital Expenditures declined to $5324.0 in Q2 2025 per NTRB's latest filing, from $46958.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $49137.0 in Q1 2024 and troughed at $1272.0 in Q4 2022.
- A 5-year average of $22144.8 and a median of $17411.5 in 2021 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2023 and 2024: Capital Expenditures slumped 94.01% in 2023, then surged 390.24% in 2024.
- Over 5 years, Capital Expenditures stood at $1992.0 in 2021, then tumbled by 36.14% to $1272.0 in 2022, then soared by 106.29% to $2624.0 in 2023, then surged by 1689.56% to $46958.0 in 2024, then slumped by 88.66% to $5324.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $5324.0, $46958.0, and $38890.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 5,324.00 |
| Apr 30, 2025 | 5,324.00 |
| Oct 31, 2024 | 46,958.00 |
| Oct 31, 2024 | 46,958.00 |
| Jul 31, 2024 | 38,890.00 |
| Jul 31, 2024 | 38,890.00 |
| Apr 30, 2024 | 6,195.00 |
| Apr 30, 2024 | 6,195.00 |
| Jan 31, 2024 | 49,137.00 |
| Jan 31, 2024 | 49,137.00 |
| Apr 30, 2023 | 2,624.00 |
| Apr 30, 2023 | 2,624.00 |
| Jan 31, 2023 | 10,023.00 |
| Jan 31, 2023 | 10,023.00 |
| Oct 31, 2022 | 1,272.00 |
| Oct 31, 2022 | 1,272.00 |
| Jul 31, 2022 | 24,206.00 |
| Jul 31, 2022 | 24,206.00 |
| Apr 30, 2022 | 43,803.00 |
| Apr 30, 2022 | 43,803.00 |